Michael S. Seaman

This study shows that sequential vaccination can mature VRC01-class B cells into antibodies that neutralize a broad range of HIV-1 viruses.

This study shows that structure-guided vaccination can elicit broadly neutralizing antibodies targeting the HIV-1 silent face, expanding vaccine strategies.

This paper develops a cell-based therapy that enables sustained, dose-tunable delivery of monoclonal antibodies through a single administration, demonstrating long-term efficacy and safety in preclinical models.

This study demonstrates that lipid nanoparticle-formulated RNA encoding a potent HIV-1 neutralizing antibody can durably suppress viremia in humanized mice.

This paper presents an RNA-encoded bNAb platform for in vivo production of PGT121-LS, showing prolonged half-life and potent neutralization in mice and non-human primates.

This paper develops a mouse model to study and overcome challenges in maturing HIV-1 broadly neutralizing antibodies by expressing a stalled VRC01 intermediate in germinal center B cells.

This paper develops updated HIV-1 pseudovirus panels to better detect and assess B cell lineages with potential to produce broadly neutralizing antibodies against contemporary HIV-1 variants.

This study uses gene-edited hematopoietic stem cells to create long-lived B lymphocyte protein factories that produce therapeutic antibodies against HIV-1, malaria, and influenza.

This paper develops a gp120-specific CD4 variant (gCD4) that improves thermostability, reduces off-target class II MHC binding, and enhances HIV-1 neutralization compared to existing CD4-Ig biologics.

The paper models SARS-CoV-2 evolution during the pandemic, finding that immune escape became more important than infectivity as variants evolved.

This study designs a dual-epitope vaccine targeting HIV-1 Env's fusion peptide and V2 apex, showing it elicits neutralizing antibodies against both sites in rhesus macaques.

This study evaluates how monoclonal and polyclonal human antibodies protect humanized mice from HIV-1 infection, showing that both neutralization and Fc-mediated effects contribute to protection.

This study improves HIV broadly neutralizing antibodies through multistate engineering, resulting in enhanced breadth and potency against diverse Env variants.

This study shows a novel two-step mechanism for inducing broadly neutralizing HIV antibodies in macaques using a modified SHIV, informing vaccine design.

This paper identifies a potent, broad neutralizing antibody targeting a glycan-independent V3 epitope on HIV-1 Env, showing enhanced neutralization potency and resistance to escape mutations.

The paper identifies a new broadly neutralizing antibody, 04_A06, with high potency and breadth against HIV-1 strains, showing potential for prevention and therapy.

This study isolates and characterizes V2 apex-directed neutralizing antibodies from SHIV-infected macaques, revealing structural and genetic features that enable broad neutralization.

This study shows that transient glycan deletions in SHIVs can induce CD4-binding site broadly neutralizing antibodies in macaques, offering a model for HIV vaccine design.

This paper develops a hydrogel depot system to prolong the release of broadly neutralizing antibodies, showing improved pharmacokinetics and reduced immune cell-mediated release through co-formulation with anti-inflammatory agents.

This study engineers an HIV broadly neutralizing antibody to improve its potency, antiviral activity, and manufacturability while maintaining safety and efficacy.

The paper identifies minimal somatic hypermutations required for CD4bs bNAb neutralization breadth and uses structural data to guide HIV-1 vaccine immunogen design.